Overview

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

Status:
Not yet recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This is a double blind, randomised, non-clinical study with 2 groups (1 investigational group and 1 comparator group) aiming to assess the effectiveness of PEA for reducing eczema severity compared to a base comparator moisturiser in healthy adults aged over 18 years.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

RDC Clinical Pty Ltd

Treatments:

Palmidrol